Alantolactone suppresses human osteosarcoma through the PI3K/AKT signaling pathway
- Yong Zhang
- Qiuyan Weng
- Jinming Han
- Jianming Chen
Affiliations: Department of Trauma Orthopedics, Ningbo No. 6 Hospital, Ningbo, Zhejiang 315000, P.R. China, Department of Neurology, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, Zhejiang 315000, P.R. China, Department of Spinal Surgery, Ningbo No. 6 Hospital, Ningbo, Zhejiang 315000, P.R. China
- Published online on: December 13, 2019 https://doi.org/10.3892/mmr.2019.10882
Copyright: © Zhang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Osteosarcoma is the most common type of malignant bone cancer and results in cancer‑related deaths among adolescents. Alantolactone (ALT) demonstrates antitumor properties in various diseases; however, its potential role in osteosarcoma is relatively unclear. The aim of the present study was to evaluate the effect of ALT on osteosarcoma. ALT significantly decreased the viability of U2OS and HOS osteosarcoma cell lines. Cells flow cytometry assay and Hoechst 33258 staining assay revealed that ALT significantly increased the proportion of apoptotic U2OS cells. In addition, wound healing and Transwell invasion assays demonstrated that the invasion and migration of osteosarcoma were markedly reduced upon ALT treatment. It was hypothesized that the antitumor functions of ALT are mediated through inhibition of the PI3K/AKT signaling pathway. In conclusion, the results of the present study confirmed the inhibition of ALT on osteosarcoma cells via downregulation of PI3K/AKT signaling pathways, suggesting ALT as a potential therapeutic candidate for osteosarcoma.